The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

Fri, 09th Feb 2024 18:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by Kyverna Therapeutics regarding its pricing of a USD319 million initial public offering, upsized USD137 million above its initial estimate last week. Kyverna is a clinical-stage cell therapy biopharma company, in which RTW initially invested through a Series B funding round in early 2022. On the first day of trading, Kyverna's share price traded up by 36% to close at USD30.00 per share.

----------

Symphony Environmental Technologies PLC - Hertfordshire-based firm developing technology to make plastic biodegradable - Says that the General Court of the European Union found that the defendants didn't exceed "the limits of their discretion", so Symphony is not entitled to compensation. However, Symphony explains that the judgement was not an assessment of the effectiveness of the d2w technologies. Adds that the court didn't include further studies that have supported the technology, as well as the distinction between oxo-biodegradable and oxo-degradable plastics. Says that d2w technology has not been widely used in the EU for several years, and the lengthy legal process and judgment has "very little effect" on existing business.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes dispute with Stalicla SA, its partner in autism spectrum disorder and other neurodevelopmental disorders. Explains that in October 2022, Evgen licensed the rights for its lead asset, SFX-01, to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study. Evgen, having completed a Phase 1b study, believes the next payment is now due, and says it has formally implemented the dispute resolution process. It had not anticipated any milestone payments from Stalicla in its financial forecasting, and its cash runway remains unchanged.

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Signs investment deal with Indico Investments and Management SL, for a maximum of EUR2.0 million. The investment commitment, which expires on February 7, relates to the company's Class A shares. It will be carried out in tranches of EUR500,000, with a discount of 10%.

----------

DCI Advisors Ltd - British Virgin Islands-based real estate investment company - Says it has entered another loan agreement for EUR350,000 with a shareholder to provide additional working capital. The shareholder providing this loan previously entered into a loan agreement with DCI Advisors for EUR350,000 last October. To date, DCI has received seven loans of EUR350,000 each and two loans from funds managed by a single shareholder amounting to USD330,000 in aggregate.

----------

Apax Global Alpha Ltd - Guernsey-based investor in technology, services, healthcare, internet and consumer - Confirms that the offer of 120 pence in cash per Kin and Carta PLC share is final and will not be increased. In December, Apax said that a 'no increase statement' relating to its own offer price was no longer in effect and had been set aside, after Kin & Carta accepted an offer of 130p per share from Valtech, a company controlled by funds advised by London-based BC Partners LLP.

----------

Sutton Harbour Group PLC - Plymouth, England-based waterfront regeneration specialist - Notes press statement made by Plymouth City Council on Thursday, and confirms that it has received a letter from the Council alleging a breach of the Plymouth City Airport lease. Says that it is considering, in conjunction with its advisers, the contents of the letter, and will provide an update in due course.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 Aug 2023 10:09

AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
13 Jul 2023 15:58

UK shareholder meetings calendar - next 7 days

Friday 14 July 
Templeton Emerging Markets Investment Trust PLCAGM
Monday 17 July 
All ThingsConsidered Group PLCAGM
Tower Resources PLCAGM
Tuesday 18 July 
Alkemy Capital Investments PLCAGM
Bloomsbury Publishing PLCAGM
CT Property Trust LtdGM re takeover by LondonMetric Property
e-Therapeutics PLCAGM
MobilityOne LtdEGM re Tete planned JV deadline extension
SmartSpace Software PLCAGM
Strategic Minerals PLCAGM
Wynnstay Properties PLCAGM
Wednesday 19 July 
Berkeley Energia LtdAGM
Caledonian Trust PLCAGM
DG Innovate PLCAGM
Experian PLCAGM
HICL Infrastructure PLCAGM
Mind Gym PLCAGM
Sportech PLCGM re share capital restructure
Triple Point Income VCT PLCAGM
Thursday 20 July 
ACG Acquisition Co LtdEGM re acquisition of the Atlantic Nickel
Big Yellow Group PLCAGM
CT UK High Income Trust PLCAGM
Evgen Pharma PLCAGM
FD Technologies PLCAGM
Fuller, Smith & Turner PLCAGM
GB Group PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
International Distributions Services PLCAGM
Fidelity China Special Situations PLCAGM
Johnson Matthey PLCAGM
Kingspan Group PLCEGM re delisting
Pennon Group PLCAGM
Premier Foods PLCAGM
Premier Miton Group PLCAGM
Qinetiq Group PLCAGM
SSE PLCAGM
TR Property Investment Trust PLCAGM
VP PLCAGM
Weiss Korea Opportunity Fund LtdAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
27 Jun 2023 10:17

AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 10:01

Evgen Pharma's SFX-01 has positive effects for treating a rare cancer

(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome.

Read more
19 Jun 2023 10:05

Evgen collaborator receives grant from KWF Dutch Cancer Society

(Alliance News) - Evgen Pharma PLC on Monday said its collaborator at the Erasmus University Medical Center in Rotterdam has received notice of a grant from KWF Dutch Cancer Society.

Read more
7 Jun 2023 11:41

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

(Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July.

Read more
31 May 2023 15:46

UK earnings, trading statements calendar - next 7 days

Thursday 1 June 
Auto Trader Group PLCFull Year Results
Dr Martens PLCFull Year Results
Pennon Group PLCFull Year Results
Trinity Exploration & Production PLCFull Year Results
Friday 2 June 
TR Property Investment Trust PLCFull Year Results
Nostrum Oil & Gas PLCFull Year Results
Monday 5 June 
Celadon Pharmaceuticals PLCFull Year Results
Hercules Site Services PLCHalf Year Results
Itaconix PLCFull Year Results
Sirius Real Estate LtdFull Year Results
ValiRx PLCFull Year Results
Verici Dx PLCFull Year Results
Tuesday 6 June 
British American Tobacco PLCTrading Statement
Chemring Group PLCHalf Year Results
Ferguson PLCQ3 Results
Gooch & Housego PLCHalf Year Results
Jadestone Energy PLCFull Year Results
N Brown Group PLCFull Year Results
NewRiver REIT PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Paragon Banking Group PLCHalf Year Results
Speedy Hire PLCFull Year Results
Warehouse REIT PLCFull Year Results
Wednesday 7 June 
discoverIE Group PLCFull Year Results
Evgen Pharma PLCFull Year Results
LXi REIT PLCFull Year Results
Ramsdens Holdings PLCHalf Year Results
Residential Secure Income PLCHalf Year Results
Vp PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Mar 2023 11:10

IN BRIEF: Evgen Pharma shares up as pharmacokinetic data announced

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter.

Read more
22 Mar 2023 10:30

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
16 Mar 2023 16:35

Evgen notes evidence of radiosensitisation by SFX-01 in cancer cells

(Alliance News) - Evgen Pharma PLC said on Thursday it had found further evidence of radiosensitisation by SFX-01 in sarcoma cells.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jan 2023 10:40

Evgen Pharma completes dosing of clinical trial for SFX-01 tablet

(Alliance News) - Evgen Pharma PLC on Wednesday said it completed the dosing of all three cohorts of the phase 1/1b clinical trial of its SFX-01 tablet formulation.

Read more
8 Dec 2022 13:57

Evgen Pharma loss, operating expenses widen; SFX-01 study on schedule

(Alliance News) - Evgen Pharma PLC on Thursday said interim loss widened, but noted the healthy volunteer study of its SFX-01 formulation remains on schedule.

Read more
16 Nov 2022 16:11

Evgen Pharma starts clinical trial of new SFX-01 tablet

(Alliance News) - Evgen Pharma PLC said on Wednesday it had started a randomised, placebo-controlled clinical trial of its new SFX-01 tablet.

Read more
16 Nov 2022 14:05

Evgen Pharma doses first volunteers in SFX-01 trial

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.